Illumina helped the digital PCR technology developer secure fresh convertible bond and loan financing that will be used for international expansion and the further development of its platform.
France-based DNA quantification technology developer Stilla Technologies has raised €31.3m ($35m) in debt and convertible bond financing from investors including Illumina Ventures, the corporate venturing arm of genomics technology producer Illumina.
The round also featured BNP Paribas Développement, a subsidiary of financial services firm BNP Paribas, as well as LBO France, Eurazeo, Kurma Partners, TusPark Capital Management, Casdin Capital and European Investment Bank. It consisted of $13m in convertible bonds and $22m in loan financing.
Stilla has developed a digital…
